| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | BESC2; ENaCa; SCNEA; SCNN1; ENaCalpha |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SCNN1A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SCNN1A抗体的3篇代表性文献(注：以下内容基于真实研究领域方向模拟，具体文献需根据实际数据库检索验证)：
---
1. **文献名称**：*"Characterization of a novel monoclonal antibody targeting the SCNN1A subunit of the epithelial sodium channel"*
**作者**：Zhang L, et al.
**摘要**：本研究报道了一种新型单克隆抗体(mAb-3C2)的开发和表征，该抗体特异性靶向SCNN1A(ENaC α亚基)。通过免疫印迹和免疫组化验证，该抗体能有效识别天然和重组SCNN1A蛋白，并应用于肾脏组织ENaC表达的定量分析，为高血压相关研究提供工具。
---
2. **文献名称**：*"SCNN1A mutations and antibody-based detection in pseudohypoaldosteronism type 1"*
**作者**：Edelheit O, et al.
**摘要**：文章分析了假性醛固酮减少症1型(PHA1)患者的SCNN1A基因突变，并利用特异性抗体检测患者上皮细胞中SCNN1A蛋白的异常表达，揭示了突变导致ENaC功能丧失的分子机制，为遗传诊断提供抗体检测方法。
---
3. **文献名称**：*"Role of SCNN1A in airway inflammation: Insights from antibody-mediated inhibition studies"*
**作者**：Harris JK, et al.
**摘要**：通过使用SCNN1A中和抗体阻断ENaC活性，研究证实了SCNN1A在气道钠离子转运和黏液过度分泌中的作用，提示其作为慢性阻塞性肺病(COPD)治疗的潜在靶点。
---
如需具体文献，建议在PubMed或Web of Science中检索关键词“SCNN1A antibody”或“ENaC alpha antibody”获取最新研究。
The SCNN1A antibody targets the α-subunit of the epithelial sodium channel (ENaC), encoded by the *SCNN1A* gene. ENaC, a heterotrimeric protein composed of α, β, and γ subunits, regulates sodium reabsorption in epithelial tissues, notably in the kidneys, lungs, and colon. The α-subunit (SCNN1A) is essential for channel assembly and function, influencing fluid homeostasis, blood pressure regulation, and airway surface liquid balance. Dysregulation of ENaC activity is linked to pathologies such as hypertension, pulmonary edema, Liddle syndrome (a hereditary form of hypertension), and cystic fibrosis-related sodium hyperabsorption.
SCNN1A antibodies are widely used in research to study ENaC expression, localization, and functional modulation under physiological or disease conditions. They enable detection of SCNN1A via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in investigations of ENaC trafficking, post-translational modifications (e.g., proteolytic cleavage), and interactions with regulatory proteins (e.g., aldosterone or proteases). These antibodies also support clinical research into ENaC-targeted therapies, such as inhibitors for cystic fibrosis or hypertension. Validating antibody specificity is critical due to structural similarities among ENaC subunits and potential cross-reactivity.
×
